CSI Market
Sign In | Register

Abeona Therapeutics Inc (ABEO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ABEO quarterly Cash Flow →
Examining cash flow movements between Abeona Therapeutics Inc and Dec 31 2021 reveals how Dec 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income71.18
Depreciation & amortization2.55
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-5.49
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation10.78
Noncash Contribution Expense1.15
Fair Value Adjustment of Warrants-6.14
Derivative Gain On Derivative-
Derivative Loss On Derivative-
Gain On Negotiated Accounts Payable-
Derivative Gain Loss On Derivative Net-
Warrant Extension Expense-
Common Stock Issued To Employees And Directors-
Common Stock Issued To Directors And Employees-
Increase Decrease In Interest Payable On Dividends-
Increase Decrease Right Of Use Assets And Other Assets-
Allocated Share Based Compensation Expense Restricted Stock-
Increase Decrease In Accounts Payable And Accrued And Lease Liabilities-
Accretion And Interest On Shortterm Investments-
Operating Lease Impairment Loss-
Gain On Settlement Of Related Party-
Operating Lease Right Of Use Asset Amortization Expense-152.37
Increase Decrease In Operating Lease Liability-0.58
Income taxes0.13
Unrealized Gain (Loss) on Derivatives0.00
Accounts Receivable-5.06
Accounts Payable6.54
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.15
Other Working Capital-0.77
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.90
Discontinued operations0.00
Net Cash flow from Operating Activities-76.33
Investing Activities
Capital Expenditures-7.98
Sale of Capital Items0.00
Short-term Investments Proceeds113.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Payments For Sale And Maturity Of Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities105.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock26.08
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-102.17
Proceeds From Issuance Of Common Stock Net Of Costs-
Proceeds From Issuance Of Common Stock Two Net Of Costs-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Business Combination Contingent Consideration-
Noncash Or Part Noncash Acquisition Licensed Tecnology-
Liabilities Assumed-
Significantnoncashtransactionvalueofsharesissued-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents78.44
Proceeds From Issuance Public Offering With Common Stock And Warrants-
Proceeds From Warrant Exercises One-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations23.70
Proceeds From Issuance Of Common Stock And Prefunded Warrants In Public Offering Net Of Offering Costs-
Proceeds From Issuance Of Common Stock And Warrants In Public Offering Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities26.04
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-84.30
Total Cash Flow54.74
4 historic quarters locked

Sign in to unlock the full Abeona Therapeutics Inc cash flow history.

Sign In Create Free Account

About Abeona Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 17, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-010413

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License